| IRI | immunoreactive insulin; insulin resistance index |
|---|---|
| IRS | immunoreactive secretion; infrared spectrophotometry; insulin receptor species; insulin receptor sub... |
| IST | inappropriate sinus tachycardia; insulin sensitivity test; insulin shock therapy; International Soci... |
| ZPP | Zinc Proto-Porphyrin |
| AEZ | acrodermatitis enteropathica, zinc deficient |
| zinc radioisotopes | Unstable isotopes of zinc that decay or disintegrate emitting radiation. Zn atoms with atomic weights 60-63, 65, 69, 71, and 72 are radioactive zinc isotopes. (12 Dec 1998) |
|---|---|
| zinc stearate | A zinc compound with variable proportions of stearic and palmitic acids; a water-repellent, protective agent used in powders and ointments in the treatment of eczema, acne, and other skin diseases. (05 Mar 2000) |
| zinc sulfate | <chemical> A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (reynolds jef(ed): martindale: the extra pharmacopoeia (electronic version). Micromedex, inc, englewood, co, 1995) Pharmacological action: astringents. Chemical name: Sulfuric acid, Zinc salt (1:1) (12 Dec 1998) |
| zinc sulfate flotation centrifugation method | A flotation method in which the faecal specimen is suspended in tap water, strained through wet gauze, centrifuged, resuspended in tap water, washed and recentrifuged several times, and then suspended in 33% solution of zinc sulfate and centrifuged at top speed for 45 to 60 sec; a bacteriologic loop may be used to pick up the surface layer, which contains protozoan cysts and helminth eggs. (05 Mar 2000) |
| zinc sulfocarbolate | Used as an intestinal antiseptic and locally as an astringent in chronic inflammation of the mucous membranes. Synonym: zinc sulfocarbolate. (05 Mar 2000) |
| zinc superoxide | ZnO2;a yellowish white powder, insoluble in water and decomposed by acids; used in pharmaceutical preparations. Synonym: zinc superoxide. (05 Mar 2000) |
| zinc undecylenate | Zinc undecenoate, [CH2==CH(CH2)8COO]2Zn;the zinc salt of undecylenic acid; used in the treatment of fungal and other affections of the skin, including psoriasis. (05 Mar 2000) |
| zinc white | <chemical> A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock. Pharmacological action: dermatologic agents, sunscreening agents. Chemical name: Zinc oxide (ZnO) (12 Dec 1998) |
| unmodified zinc oxide-eugenol cement | A dental cement obtained by mixing zinc oxide and eugenol without modifiers. (05 Mar 2000) |
| flowers of zinc | <chemical> A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock. Pharmacological action: dermatologic agents, sunscreening agents. Chemical name: Zinc oxide (ZnO) (12 Dec 1998) |
| anti-insulin | A factor, usually an antibody, which antagonises the action of insulin. (05 Mar 2000) |
| anti-insulin antibody | A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result. (27 Sep 1997) |
| biphasic insulin | <protein> A type of insulin that is a mixture of intermediate- and fast-acting insulin. (09 Oct 1997) |
| receptors, insulin | Cell surface proteins that bind insulin and trigger intracellular changes which influence the behaviour of cells. The best understood physiological consequence of insulin receptor activation is increased transport of glucose into most cells, which controls the rate of carbohydrate metabolism. The insulin receptor is a multifunctional protein complex that has intrinsic tyrosine kinase activity and is capable of autophosphorylation. (12 Dec 1998) |
| receptors, insulin-like-growth factor I | Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity. (12 Dec 1998) |